ER-positive and HER2-negative disease is both clinically and biologically heterogeneous and several characteristics including tumor size, malignancy grade, Ki67, PR, and genomic profiles have been associated with the ability to achieve pCR7–11. The gene discussed is ERBB2; the disease is neoplasm.